The SCS market is still down YoY, but improved sequentially as companies get back on track
Among the many topics covered in the complete, comprehensive Q319 SCS Market Recap* are:
- Complete SCS Market Overview
- Abbott Down But Still No. 1
- Nevro Returns to Positive Growth
- Boston Scientific Down But Growing Above Market
- Medtronic Shares Up and Down
- Nuvectra Suspends Sales of Algovita SCS
- Select Regulatory News
YTD through Q319, US SCS revenues are trending at -3.5% YoY ($
), a lower rate than SmartTRAK’s original 2019 forecast of +6.1%. Our more positive outlook assumed planned product launches would provide a greater contribution to market growth in H219 and that NVTR would still be competing in the market. However, SmartTRAK believes...
*The entire unedited article can only be viewed by SmartTRAK subscribers to this module. For information on how to subscribe, please click the button below.
